Business Trip

59 Episodes

1. The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)

   Published: 05/06/2022
2. Empowering the next wave of psychedelic therapists: Journey Clinical

   Published: 23/05/2022
3. Osmind and the future of electronic health records in psychedelic medicine

   Published: 18/04/2022
4. Palo Santo on investing in 2nd gen psychedelics and public markets

   Published: 21/03/2022
5. Designing psychedelic mindstates, with Mindstate Design Labs

   Published: 10/02/2022
6. PsyMed Ventures, our venture fund to invest in psychedelic medicine & mental health tech

   Published: 10/01/2022
7. MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy

   Published: 24/11/2021
8. On transformational ketamine therapy and running an integrative psychedelic clinic

   Published: 28/10/2021
9. The new frontiers of DMT therapies

   Published: 06/10/2021
10. Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde

    Published: 13/08/2021
11. Analyzing the atai Life Sciences IPO

    Published: 10/06/2021
12. A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx

    Published: 04/05/2021
13. Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney

    Published: 16/03/2021
14. How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka

    Published: 24/02/2021
15. From serving medicine to company founder: NANA founder Flor Bollini

    Published: 05/01/2021
16. Helping psychedelic practitioners through software: Maya Health CEO David Champion

    Published: 19/10/2020
17. How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer

    Published: 17/09/2020
18. Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin

    Published: 13/08/2020
19. Dylan Beynon: ketamine-assisted therapy for anxiety and depression

    Published: 21/06/2020